nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

01.08.2012 | Reproductive Medicine

Use of progestogens in pregnant and infertile patients

verfasst von: Tülay Özlü, Ayşenur Çakır Güngör, Melahat Emine Dönmez, Bülent Duran

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Progesterone is an essential hormone in the occurence and maintenance of pregnancy. Natural or synthetic progestogens are commonly used in pregnant patients or patients undergoing infertility treatments for various indications. Most frequently put indications for the use of progestogens in these patient populations are the prevention of spontaneous preterm birth, the prevention of pregnancy loss in pregnancies with an unexplained recurrent pregnancy loss and in patients with threatened abortion. It is also used in pregnant women undergoing nonobstetric surgery, for infertility or recurrent pregnancy loss that is thought to be due to luteal phase defect or as a luteal support in stimulated IVF cycles. We aimed to review the current evidence for the use of progestogens in each of these settings.

Cunningham FG (ed) (2010) Williams obstetrics, 23rd edn. McGraw-Hill, New York

Carey WD (ed) (2009) Cleveland clinic current clinical medicine, 2nd edn. Saunders, Philadelphia

Gabbe SG (ed) (2007) Gabbe: obstetrics: normal and problem pregnancies, 5th edn. Churchill Livingstone, Philadelphia

Meis PJ, Connors N (2004) Progesterone treatment to prevent pre-term birth. Clin Obstet Gynecol 47:784–795PubMedCrossRef

Stites DP, Bugbee S, Siiteri PK (1983) Differential action of progesterone and cortisol on lymphocyte and monocyte interaction during lymphocyte activation—relevance to immunosuppression in pregnancy. J Reprod Immunol 5:215–228PubMedCrossRef

Palagiano A, Bulletti C, Pace MC, De Ziegler D, Cicinelli E, Izzo A (2004) Effects of vaginal progesterone on pain and uterine contractility in patients with threatened abortion before twelve weeks of pregnancy. Ann NY Acad Sci 1034:200–210PubMedCrossRef

Dodd JM, Flenady V, Cincotta R, Crowther CA (2006) Prenatal administration of progesterone for preventing preterm birth. Cochrane Database Syst Rev 25(1):CD004947

Nielsen S, Hahlin M, Platz-Christensen J (1999) Randomised trial comparing expectant with medical management for first trimester miscarriage. Br J Obstet Gynaecol 106:804–807PubMedCrossRef

Tang OS, Chan CC, Ng EH, Lee SW, Ho PC (2003) A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. Hum Reprod 18(11):2315–2318PubMedCrossRef

10.

Majhi P, Bagga R, Kalra J, Sharma M (2009) Intravaginal use of natural micronised progesterone to prevent pre-term birth: a randomised trial in India. J Obstet Gynaecol 29(6):493PubMedCrossRef

11.

US Department of Health and Human Services (2011) Food and Drug Administration Statement on Makena.(press release), 30 Mar 2011 US Department of Health and Human Services, Silver Spring

12.

Omar MH, Mashita MK, Lim PS, Jamil MA (2005) Dydrogesterone in threatened abortion: pregnancy outcome. J Steroid Biochem Mol Biol 97(5):421–425 Epub 2005 Nov 15PubMedCrossRef

13.

Gruber CJ, Huber JC (2005) The role of dydrogesterone in recurrent (habitual) abortion. J Steroid Biochem Mol Biol 97(5):426–430 Epub 2005 Sep 26PubMedCrossRef

14.

Mattison DR, Damus K, Fiore E, Petrini J, Alter C (2001) Preterm delivery: a public health perspective. Paediatr Perinat Epidemiol 15(Suppl 2):7–16PubMedCrossRef

15.

Iams JD, Romero R, Culhane JF, Goldenberg RL (2008) Primary, secondary, and tertiary interventions to reduce the morbidity and mortality of preterm birth. Lancet 371(9607):164PubMedCrossRef

16.

Tita AT, Rouse DJ (2009 Mar) Progesterone for preterm birth prevention: an evolving intervention. Am J Obstet Gynecol 200(3):219–224PubMedCrossRef

17.

Newman RB, Campbell BA, Stramm SL (1990) Objective tocodynamometry identifies labor onset earlier than subjective maternal perception. Obstet Gynecol 76:1089–1092PubMed

18.

Yemini M, Borestein R, Dreazen E, Apelman Z, Molginer BM, Kessler I et al (1985) Prevention of premature labor by 17 α-hydroxyprogesterone caproate. Am J Obstet Gynecol 151:574–577PubMed

19.

Dodd JM, Flenady VJ, Cincotta R, Crowther CA (2008) Progesterone for the prevention of preterm birth: a systematic review. Obstet Gynecol 112(1):127PubMedCrossRef

20.

Waters TP, Schultz BA, Mercer BM, Catalano PM (2009) Effect of 17alpha-hydroxyprogesterone caproate on glucose intolerance in pregnancy. Obstet Gynecol 114(1):45PubMed

21.

Rebarber A, Istwan NB, Russo-Stieglitz K, Cleary-Goldman J, Rhea DJ, Stanziano GJ et al (2007) Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery. Diabetes Care 30(9):2277–2280 Epub 2007 Jun 11PubMedCrossRef

22.

National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network., 4 (2009) The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. Am J Obstet Gynecol 201(4):392.e1CrossRef

23.

Rebarber A, Ferrara LA, Hanley ML, Istwan NB, Rhea DJ, Stanziano GJ et al (2007) Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 196(3):224.e1CrossRef

24.

Briery CM, Veillon EW, Klauser CK, Martin RW, Magann EF, Chauhan SP, Morrison JC (2011) Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. Am J Obstet Gynecol 204(1):54.e1-5PubMedCrossRef

25.

Norman JE, Mackenzie F, Owen P, Mactier H, Hanretty K, Cooper S et al (2009) Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis. Lancet 373(9680):2034PubMedCrossRef

26.

Obstetrix Collaborative Research Network (2011) 17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol 204(3):221.e1CrossRef

27.

PREDICT Group (2011) Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol 38(3):272CrossRef

28.

National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network (2010) Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17-αhydroxyprogesterone caproate. J Matern Fetal Neonatal Med 23(12):1360CrossRef

29.

PREDICT Group (2011) Vaginal micronized progesterone and risk of preterm delivery in high-risk twin pregnancies: secondary analysis of a placebo-controlled randomized trial and meta-analysis. Ultrasound Obstet Gynecol 38(3):281CrossRef

30.

National Institute of Child Health and Human Development (NICHD), Maternal-Fetal Medicine Units Network (MFMU) (2009) Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Obstet Gynecol 113(2 Pt 1):285

31.

Obstetrix Collaborative Research Network (2010) Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol 203(3):248.e1CrossRef

32.

Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH (2007) Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 357:462–469PubMedCrossRef

33.

Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M (2000) Maternal age and fetal loss: population based register linkage study. Br Med J 320:1708–1712CrossRef

34.

Wilcox AJ, Weinberg CR, O’Connor JF (1988) Incidence of early loss of pregnancy. N Engl J Med 319:189–194PubMedCrossRef

35.

Abramson J, Stagnaro-Green A (2001) Thyroid antibodies and fetal loss: an evolving story. Thyroid 11(1):57PubMedCrossRef

36.

Li TC, Iqbal T, Anstie B, Gillham J, Amer S, Wood K et al (2002) An analysis of the pattern of pregnancy loss in women with recurrent miscarriage. Fertil Steril 78(5):1100–1106PubMedCrossRef

37.

Haas DM, Ramsey PS (2008) Progestogen for preventing miscarriage. Cochrane Database Syst Rev 16(2):CD003511

38.

Coomarasamy A, Truchanowicz EG, Rai R (2011) Does first trimester progesterone prophylaxis increase the live birth rate in women with unexplained recurrent miscarriages? BMJ 342:d1914PubMedCrossRef

39.

Choi BC, Polgar K, Xiao L, Hill JA (2000) Progesterone inhibits in vitro embryotoxic Th1 cytokine production to trophoblast in women with recurrent pregnancy loss. Hum Reprod 15(Suppl 1):46PubMedCrossRef

40.

World Health Organization (1992) International statistical classification of diseases and related health problems, vol 1, 10th edn. World Health Organization, Geneva

41.

Wahabi HA, Abed Althagafi NF, Elawad M, Al Zeidan RA (2011) Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev 16(3):005943

42.

Gerhard I, Gwinner B, Eggert-Kruse W, Runnebaum B (1987) Doubleblind controlled trial of progesterone substitution in threatened abortion. Biol Res Pregnancy Perinatol 8:26–34PubMed

43.

Silver RI, Rodriguez R, Chang TS, Gearhart JP (1999) In vitro fertilization is associated with an increased risk of hypospadias. J Urol 161(6):1954–1957PubMedCrossRef

44.

Dudas I, Gidai J, Czeizel AE (2006) Population-based case-control teratogenic study of hydroxyprogesterone treatment during pregnancy. Congenit Anom 46(4):194–198CrossRef

45.

Katz Z, Lancet M, Skornik J, Chemke J, Mogilner BM, Klinberg M (1985) Teratogenicity of progestogens given during the first trimester of pregnancy. Obstet Gynecol 65(6):775–780PubMed

46.

El-Zibdeh MY, Yousef LT (2009) Dydrogesterone support in threatened miscarriage. Maturitas 65(Suppl 1):S43–S46 Epub 2009 Dec 14.PubMedCrossRef

47.

Pandian RU (2009) Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas 65(Suppl 1):S47–S50 Epub 2009 Dec 14PubMedCrossRef

48.

Regan L, Rai R (2000) Epidemiology and the medical causes of miscarriage. Baillieres Best Pract Res Clin Obstet Gynaecol 14(5):839PubMedCrossRef

49.

Balasch J, Fábregues F, Creus M, Vanrell JA (1992) The usefulness of endometrial biopsy for luteal phase evaluation in infertility. Hum Reprod 7(7):973PubMed

50.

Davis OK, Berkeley AS, Naus GJ, Cholst IN, Freedman KS (1989) The incidence of luteal phase defect in normal, fertile women, determined by serial endometrial biopsies. Fertil Steril 51(4):582PubMed

51.

Ogasawara M, Kajiura S, Katano K, Aoyama T, Aoki K (1997) Are serum progesterone levels predictive of recurrent miscarriage in future pregnancies? Fertil Steril 68(5):806–809PubMedCrossRef

52.

Ubaldi F, Bourgain C, Tournaye H, Smitz J, Van Steirteghem A, Devroey P (1997) Endometrial evaluation by aspiration biopsy on the day of oocyte retrieval in the embryo transfer cycles in patients with serum progesterone rise during the follicular phase. Fertil Steril 67:521–526PubMedCrossRef

53.

Macklon NS, Fauser BC (2000) Impact of ovarian hyperstimulation on the luteal phase. J Reprod Fertil 55(Suppl):101–108

54.

Burney RO, Schust DJ, Yao MWM (2006) Infertility. In: Berek JS (ed) Berek & Novak’s Gynecology. Lippincott Williams & Wilkins, Philadelphia, pp 1185–1275

55.

Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P, Devroey P (2007) An update of luteal phase support in stimulated IVF cycles. Hum Reprod Update 13(6):581–590 Epub 2007 Jul 11PubMedCrossRef

56.

Chakravarty BN, Shirazee HH, Dam P, Goswami SK, Chatterjee R, Ghosh S (2005) Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. J Steroid Biochem Mol Biol 97:416–420PubMedCrossRef

57.

Tesarik J, Hazout A, Mendoza-Tesarik R, Mendoza N, Mendoza C (2006) Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Hum Reprod 21(10):2572–2579 Epub 2006 Aug 22PubMedCrossRef

58.

van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M (2011) Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 5(10):009154

59.

Silverberg KM, Vaughn TC, Hansard LJ, Burger NZ, Minter T (2012) Vaginal (Crinone 8 %) gel vs. intramuscular progesterone in oil for luteal phase support in in vitro fertilization: a large prospective trial. Fertil Steril 97(2):344–348 Epub 2011 Dec 19PubMedCrossRef

60.

Kyrou D, Fatemi HM, Zepiridis L, Riva A, Papanikolaou EG, Tarlatzis BC et al (2011) Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial. Hum Reprod 26(5):1020PubMedCrossRef

61.

Aboulghar MA, Amin YM, Al-Inany HG, Aboulghar MM, Mourad LM, Serour GI, Mansour RT (2008) Prospective randomized study comparing luteal phase support for ICSI patients up to the first ultrasound compared with an additional three weeks. Hum Reprod 23(4):857PubMedCrossRef

62.

Devroey P, Pados G (1998) Preparation of endometrium for egg donation. Hum Reprod Update. 4(6):856–861PubMedCrossRef

63.

Pritts EA, Atwood AK (2002) Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod 17(9):2287PubMedCrossRef

64.

Bourgain C, Devroey P, Van Waesberghe L, Smitz J, Van Steirteghem AC (1990) Effects of natural progesterone on the morphology of the endometrium in patients with primary ovarian failure. Hum Reprod 5(5):537PubMed

65.

Cicinelli E, de Ziegler D, Bulletti C, Matteo MG, Schonauer LM, Galantino P (2000) Direct transport of progesterone from vagina to uterus. Obstet Gynecol 95(3):403PubMedCrossRef

Titel: Use of progestogens in pregnant and infertile patients
verfasst von: Tülay Özlü
Ayşenur Çakır Güngör
Melahat Emine Dönmez
Bülent Duran
Publikationsdatum: 01.08.2012
Verlag: Springer-Verlag
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 2/2012
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-012-2340-4

Neu im Fachgebiet Gynäkologie und Geburtshilfe

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Use of progestogens in pregnant and infertile patients

Abstract

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Work-related repetitive strain injuries amongst practitioners of obstetric and gynaecological ultrasound worldwide

Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH)

Effect of AT1R knockdown on ishikawa cell proliferation induced by estrogen

Müllerian adenosarcoma of the uterus with heterologous elements: two case reports and literature review

Temporal trends of latency period and perinatal survival after very early preterm premature rupture of fetal membranes

Bone mineral density changes during pregnancy in actively exercising women as measured by quantitative ultrasound

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie